ETRM has been a dream for option writers. Sold FEB 2015 $1.00 puts back in June 2014 @ $0.25. Sold AUG 2014 $7.50 calls in February 2014 @ $0.30. I look at the option transactions as simply lowering my overall cost basis which currently stands at $0.6781 per share.
Based on data from Capital IQ, 175,000 shares ties you with Director Anthony Jansz as the 20th largest holder of ETRM shares currently outstanding. "Well done William, very well done!"
I'll have Randolph and Mortimer pass this information on to all of the clients at Duke & Duke. "Mr. Sharkzfanz has set the price".
As I posted several weeks back, it's just another case of "buy the rumor and sell the news". Too many posters here placed way too much emphasis on simply getting FDA approval. Yes, approval is a critical milestone, but I disagree with the premise that it's all downhill from here. The technology is potentially cutting edge, but now comes the really difficult part. ETRM needs to actually demonstrate it can sell the VBLOC in the U.S. and generate revenue. Others may think it's just the case of "build it and they will come".
Appears expensive based on 2015 estimates of $35-40 million. However, ACHI generated over $55 million of net cash from customer contracting in 2011. For me, the question is whether new management can position the business so it generates annual net cash more in the range of $60-80 million by 2016-2017. Under this scenario, the stock is currently trading at an attractive discount to intrinsic value. I don't see the stock plunging nor rising to $14 by March. I do think the filing of the 12/31/14 10-K and subsequent stock listing (this stock trades by appointment on the "pink sheets") will create a slight tailwind for the stock.